glp-1 gastrointestinal side effects of receptor agonists: mechanisms, management, and future directions EXPLORING GASTROINTESTINAL AND HEPATOBILIARY ADVERSE

If you are losing weight and tolerating the medication well at 1 mg, there is no clinical reason to increase further

Listen to Your Body Every individual health profile is unique

Changes in histone modification and DNA methylation of the StAR and Cyp19a1 promoter regions in granulosa cells undergoing luteinization during ovulation in rats

Bouyeh and Gevorgyan (6) observed a decrease followed by an increase in plasma cholesterol in birds feed Lys and Met above NRC recommendations

Friston KJ (1999)

Semaglutide (the active ingredient in Wegovy and Ozempic)[1] is a GLP-1 receptor agonist, they were testing it as a treatment for obesity